Health Care & Life Sciences » Biotechnology | RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
61.70
86.90
-
-
2,176.50
Cost of Goods Sold (COGS) incl. D&A
-
1.70
-
7.00
5.20
-
Gross Income
-
60.00
-
7.00
5.20
-
SG&A Expense
1,139.90
4,413.50
5,319.40
8,464.90
4,242.20
2,176.50
EBIT
1,139.90
4,353.50
5,239.60
8,471.90
4,247.40
2,176.50
Unusual Expense
2.00
1,719.70
167.10
187.20
-
166.40
Non Operating Income/Expense
7.20
43.60
13.30
15.70
58.20
112.60
Interest Expense
56.30
117.30
902.70
586.30
102.20
136.20
Pretax Income
1,201.50
2,707.50
5,961.90
9,229.80
4,291.50
2,591.80
Consolidated Net Income
1,201.50
2,707.50
5,961.90
9,229.80
4,291.50
2,591.80
Net Income
1,201.50
2,707.50
5,961.90
9,229.80
4,291.50
2,591.80
Net Income After Extraordinaries
1,201.50
2,707.50
5,961.90
9,229.80
4,291.50
2,591.80
Net Income Available to Common
1,201.50
12,768.30
5,968.80
9,230.90
4,291.50
2,591.80
EPS (Basic)
3.25
22.75
6.50
4.95
1.77
0.77
Basic Shares Outstanding
443.20
593.00
1,182.90
1,864.00
2,418.30
3,351.10
EPS (Diluted)
2.71
21.53
5.05
4.95
1.77
0.77
Diluted Shares Outstanding
443.20
593.00
1,182.90
1,864.00
2,418.30
3,351.10
EBITDA
1,139.90
4,351.90
5,232.50
8,464.90
4,242.20
2,176.50
Non-Operating Interest Income
-
-
0.00
0.00
-
-
Preferred Dividends
-
10,060.80
6.90
1.20
-
-

About RespireRx Pharmaceuticals

View Profile
Address
126 Valley Road
Glen Rock New Jersey 07452
United States
Employees -
Website http://www.respirerx.com
Updated 07/08/2019
RespireRx Pharmaceuticals, Inc. engages in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. It focuses on clinical development in the area of respiratory disorders, particularly sleep apneas and respiratory depression produced by drugs and neural damage, which provides the opportunities for development and commercialization of its compounds. The company was founded by Carl W.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.